Analyst Update: Oramed Pharma, Deckers Outdoor

Analysts revised their ratings and price targets on Oramed Pharmaceuticals, Inc. (ORMP) and Deckers Outdoor Corp (DECK)

May 13, 2016 at 3:17 PM
facebook X logo linkedin

Analysts are weighing in on biopharmaceutical stock Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) and shoe stock Deckers Outdoor Corp (NYSE:DECK). Here's a quick roundup of today's brokerage notes on ORMP and DECK.

  • Rodman & Renshaw reiterated a "buy" rating and lofty $25 price target for ORMP, a week before the company releases data on an oral insulin drug in development. Analysts said the data could be "transformative" for the stock, which is up 14.7%, at $7.80. Rodman & Renshaw also said ORMP's recent "licensing deal involving China rights to ORMD-0801 could be a harbinger of additional licensing transactions." The biotech stock has been chopping around the $6.50-$10 range over the past year, and CEO Nadav Kidron apparently thought it was a good time to buy, scooping up 1,000 shares for $6,953 total, per a regulatory filing. Among analysts, four out of four rate the stock a "strong buy", but traders have been quick to bet against the stock, with shorted shares representing two weeks of buying power, at ORMP's normal daily volume. 

  • DECK is down 4.1% at $51.11, after BB&T cut its rating to "underweight" from "hold", citing increased pessimism for the apparel stock, due to weak retail earnings from Macy's, Inc. (NYSE:M) and Nordstrom, Inc. (NYSE:JWN). The analysts said "we believe retailers may be less likely to chase UGG in-season, despite any potential favorable weather." Deckers Outdoor Corp shares have now surrendered more than 10% this week, giving up support atop their 160-day trendline. DECK is no stranger to skepticism, though. Before today, 10 of 13 analysts rated the stock a "hold" or worse, and 17.3% of the stock's float is sold short, an amount that would take traders 12.2 days of trading, at DECK's average daily volume, to cover.

For other stocks in analysts' crosshairs, read Analyst Upgrades: NVIDIA Corporation, Allergan plc, and Shake Shack Inc and Analyst Downgrades: Nordstrom, Inc., Dillard's, Inc., and ConforMis Inc.


Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on calls
238.5% GAIN on Oracle calls



Rainmaker Ads CGI